Anti-TCR-alphabeta monoclonal antibody R73Alternative Names: Alpha-beta-TCR monoclonal antibody R73; Anti-T-cell-receptor-alphabeta antibody R73; Anti-T-cell-receptor-alphabeta monoclonal antibody R73; Anti-TCR-alphabeta antibody R73; Monoclonal antibody R73; R73
Latest Information Update: 03 Jul 2002
At a glance
- Originator Unknown
- Developer Aventis Behring LLC; Nonindustrial source
- Class Monoclonal antibodies
- Mechanism of Action T-cell receptor antigen alpha-beta antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Transplant rejection